Ignite Creation Date:
2025-12-24 @ 5:54 PM
Ignite Modification Date:
2026-03-01 @ 3:21 AM
Study NCT ID:
NCT03321968
Status:
COMPLETED
Last Update Posted:
2023-08-04
First Post:
2017-10-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-06-23', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D007251', 'term': 'Influenza, Human'}, {'id': 'D009976', 'term': 'Orthomyxoviridae Infections'}, {'id': 'D007239', 'term': 'Infections'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrialinquiries@medicago.com', 'phone': '+1 418-658-9393', 'title': 'Medical Director', 'organization': 'Medicago'}, 'certainAgreement': {'otherDetails': 'The Investigator understands that the information in the protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical review of the study, without prior written authorization from the Sponsor. It is, however, permissible to discuss information contained in the protocol with a participant in order to obtain consent once Institutional Review Board (IRB) approval is obtained.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Day 0 (post-vaccination) up to 21 days', 'description': 'SAS. The unsolicited SAEs, unsolicited non-serious adverse events (NSAEs), and all deaths were reported.', 'eventGroups': [{'id': 'EG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.', 'otherNumAtRisk': 401, 'deathsNumAtRisk': 401, 'otherNumAffected': 94, 'seriousNumAtRisk': 401, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.', 'otherNumAtRisk': 398, 'deathsNumAtRisk': 398, 'otherNumAffected': 92, 'seriousNumAtRisk': 398, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.', 'otherNumAtRisk': 401, 'deathsNumAtRisk': 401, 'otherNumAffected': 95, 'seriousNumAtRisk': 401, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Acarodermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Ear infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Fungal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Gingival abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Localised infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Lymph gland infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Oral infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pharyngitis streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Streptococcal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Vaginal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 15, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 15, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 20, 'numAffected': 20}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Lymph node pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Lymphadenopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Food allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Aphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Disturbance in attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 4, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Dizziness exertional', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 14, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 21, 'numAffected': 20}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 17, 'numAffected': 16}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Tension headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Blepharospasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Eye swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Ocular hyperaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Ear discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Ear pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Hot flush', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Neurogenic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 8, 'numAffected': 8}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 8, 'numAffected': 8}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 18, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 15, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 9, 'numAffected': 8}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pharyngeal oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Respiratory tract congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Sinus congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Sneezing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Throat irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Abdominal pain lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Food poisoning', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Lip blister', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Lip dry', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Mouth ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 8, 'numAffected': 7}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Noninfective gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Tongue discolouration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Hepatic hypertrophy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Night sweats', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Swelling face', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Muscle tightness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Musculoskeletal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Plantar fasciitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Scoliosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Dysmenorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Urachal abnormality', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Congenital, familial and genetic disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Chills', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Hangover', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Injection site bruising', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Injection site irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Injection site joint discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Injection site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Injection site warmth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Local swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Malaise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Vaccination site pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Vessel puncture site reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Ligament sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Muscle strain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Procedural pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Road traffic accident', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Soft tissue injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Stress fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Superficial injury of eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}, {'term': 'Thermal burn', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}], 'seriousEvents': [{'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 398, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 401, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA V20.0'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'OG000'}, {'value': '383', 'groupId': 'OG001'}, {'value': '387', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'title': 'A/H1N1 (California)', 'categories': [{'measurements': [{'value': '603.7', 'groupId': 'OG000', 'lowerLimit': '541.4', 'upperLimit': '673.2'}, {'value': '595.6', 'groupId': 'OG001', 'lowerLimit': '533.9', 'upperLimit': '664.4'}, {'value': '630.6', 'groupId': 'OG002', 'lowerLimit': '565.6', 'upperLimit': '703.0'}]}]}, {'title': 'A/H3N2 (Hong Kong)', 'categories': [{'measurements': [{'value': '96.3', 'groupId': 'OG000', 'lowerLimit': '84.2', 'upperLimit': '110.1'}, {'value': '103.0', 'groupId': 'OG001', 'lowerLimit': '90.0', 'upperLimit': '117.7'}, {'value': '88.0', 'groupId': 'OG002', 'lowerLimit': '77.0', 'upperLimit': '100.6'}]}]}, {'title': 'B/Brisbane', 'categories': [{'measurements': [{'value': '41.8', 'groupId': 'OG000', 'lowerLimit': '37.8', 'upperLimit': '46.1'}, {'value': '41.9', 'groupId': 'OG001', 'lowerLimit': '38.0', 'upperLimit': '46.3'}, {'value': '38.3', 'groupId': 'OG002', 'lowerLimit': '34.7', 'upperLimit': '42.3'}]}]}, {'title': 'B/Phuket', 'categories': [{'measurements': [{'value': '215.7', 'groupId': 'OG000', 'lowerLimit': '193.2', 'upperLimit': '240.9'}, {'value': '231.1', 'groupId': 'OG001', 'lowerLimit': '206.8', 'upperLimit': '258.1'}, {'value': '235.9', 'groupId': 'OG002', 'lowerLimit': '211.3', 'upperLimit': '263.4'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.01', 'ciLowerLimit': '0.87', 'ciUpperLimit': '1.18', 'estimateComment': 'Adjusted GMT/GMT Ratio based on analysis of covariance (ANCOVA) model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'A/H1N1 (California)', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.96', 'ciLowerLimit': '0.82', 'ciUpperLimit': '1.12', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'A/H1N1 (California)', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG001', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.94', 'ciLowerLimit': '0.81', 'ciUpperLimit': '1.10', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'A/H1N1 (California)', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.94', 'ciLowerLimit': '0.77', 'ciUpperLimit': '1.13', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'A/H3N2 (Hong Kong)', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.09', 'ciLowerLimit': '0.91', 'ciUpperLimit': '1.32', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'A/H3N2 (Hong Kong)', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG001', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.17', 'ciLowerLimit': '0.97', 'ciUpperLimit': '1.41', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'A/H3N2 (Hong Kong)', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.00', 'ciLowerLimit': '0.87', 'ciUpperLimit': '1.15', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'B/Brisbane', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.09', 'ciLowerLimit': '0.95', 'ciUpperLimit': '1.26', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'B/Brisbane', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG001', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.10', 'ciLowerLimit': '0.95', 'ciUpperLimit': '1.26', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'B/Brisbane', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.93', 'ciLowerLimit': '0.80', 'ciUpperLimit': '1.09', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'B/Phuket', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG000', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.91', 'ciLowerLimit': '0.78', 'ciUpperLimit': '1.07', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'B/Phuket', 'nonInferiorityType': 'SUPERIORITY'}, {'groupIds': ['OG001', 'OG002'], 'paramType': 'Adjusted GMT Ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.98', 'ciLowerLimit': '0.84', 'ciUpperLimit': '1.15', 'estimateComment': 'Adjusted GMT/GMT Ratio based on ANCOVA model with vaccine lot as main effect and the baseline titer (log-transformed) as covariate.', 'groupDescription': 'B/Phuket', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 21 (post-vaccination)', 'description': 'The GMTs were measured using a HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). Lot-to-lot consistency was based on adjusted GMT ratio for pairwise comparisons of the lots (Lot 1 / Lot 2, Lot 1 / Lot 3, and Lot 2 / Lot 3).', 'unitOfMeasure': 'titers', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The Per Protocol (PP) analysis set consisted of the participants with no major deviations related to the analyses and with Day 0 and Day 21 immunogenicity assessments.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'OG000'}, {'value': '383', 'groupId': 'OG001'}, {'value': '387', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'title': 'A/H1N1 (California)', 'categories': [{'measurements': [{'value': '73.3', 'groupId': 'OG000', 'lowerLimit': '68.6', 'upperLimit': '77.7'}, {'value': '68.7', 'groupId': 'OG001', 'lowerLimit': '63.8', 'upperLimit': '73.3'}, {'value': '73.1', 'groupId': 'OG002', 'lowerLimit': '68.4', 'upperLimit': '77.5'}]}]}, {'title': 'A/H3N2 (Hong Kong)', 'categories': [{'measurements': [{'value': '60.9', 'groupId': 'OG000', 'lowerLimit': '55.8', 'upperLimit': '65.8'}, {'value': '63.2', 'groupId': 'OG001', 'lowerLimit': '58.1', 'upperLimit': '68.0'}, {'value': '57.4', 'groupId': 'OG002', 'lowerLimit': '52.3', 'upperLimit': '62.4'}]}]}, {'title': 'B/Brisbane', 'categories': [{'measurements': [{'value': '41.2', 'groupId': 'OG000', 'lowerLimit': '36.2', 'upperLimit': '46.3'}, {'value': '42.8', 'groupId': 'OG001', 'lowerLimit': '37.8', 'upperLimit': '48.0'}, {'value': '39.0', 'groupId': 'OG002', 'lowerLimit': '34.1', 'upperLimit': '44.1'}]}]}, {'title': 'B/Phuket', 'categories': [{'measurements': [{'value': '63.2', 'groupId': 'OG000', 'lowerLimit': '58.2', 'upperLimit': '68.0'}, {'value': '55.4', 'groupId': 'OG001', 'lowerLimit': '50.2', 'upperLimit': '60.4'}, {'value': '61.2', 'groupId': 'OG002', 'lowerLimit': '56.2', 'upperLimit': '66.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 0 (pre-vaccination) to Day 21', 'description': 'The SC rate is the percentage of participants with either a ≥ 4-fold increase in reciprocal HI titers between Day 0 and Day 21 or a rise of undetectable HI titer (i.e. \\<10) pre-vaccination (Day 0) to an HI titer of ≥40 on Day 21 post-vaccination. SC rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'PP Set.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '387', 'groupId': 'OG000'}, {'value': '383', 'groupId': 'OG001'}, {'value': '387', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'title': 'A/H1N1 (California): Day 0', 'categories': [{'measurements': [{'value': '72.3', 'groupId': 'OG000', 'lowerLimit': '67.5', 'upperLimit': '76.7'}, {'value': '76.5', 'groupId': 'OG001', 'lowerLimit': '71.9', 'upperLimit': '80.7'}, {'value': '76.7', 'groupId': 'OG002', 'lowerLimit': '72.2', 'upperLimit': '80.9'}]}]}, {'title': 'A/H1N1 (California): Day 21', 'categories': [{'measurements': [{'value': '96.1', 'groupId': 'OG000', 'lowerLimit': '93.7', 'upperLimit': '97.8'}, {'value': '97.1', 'groupId': 'OG001', 'lowerLimit': '94.9', 'upperLimit': '98.6'}, {'value': '98.7', 'groupId': 'OG002', 'lowerLimit': '97.0', 'upperLimit': '99.6'}]}]}, {'title': 'A/H3N2 (Hong Kong): Day 0', 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000', 'lowerLimit': '16.1', 'upperLimit': '24.3'}, {'value': '19.8', 'groupId': 'OG001', 'lowerLimit': '16.0', 'upperLimit': '24.2'}, {'value': '18.4', 'groupId': 'OG002', 'lowerLimit': '14.6', 'upperLimit': '22.6'}]}]}, {'title': 'A/H3N2 (Hong Kong): Day 21', 'categories': [{'measurements': [{'value': '80.3', 'groupId': 'OG000', 'lowerLimit': '76.0', 'upperLimit': '84.2'}, {'value': '79.6', 'groupId': 'OG001', 'lowerLimit': '75.3', 'upperLimit': '83.6'}, {'value': '77.5', 'groupId': 'OG002', 'lowerLimit': '73.0', 'upperLimit': '81.6'}]}]}, {'title': 'B/Brisbane: Day 0', 'categories': [{'measurements': [{'value': '13.5', 'groupId': 'OG000', 'lowerLimit': '10.2', 'upperLimit': '17.3'}, {'value': '12.3', 'groupId': 'OG001', 'lowerLimit': '9.2', 'upperLimit': '16.0'}, {'value': '13.4', 'groupId': 'OG002', 'lowerLimit': '10.2', 'upperLimit': '17.2'}]}]}, {'title': 'B/Brisbane: Day 21', 'categories': [{'measurements': [{'value': '60.1', 'groupId': 'OG000', 'lowerLimit': '55.0', 'upperLimit': '65.0'}, {'value': '59.8', 'groupId': 'OG001', 'lowerLimit': '54.7', 'upperLimit': '64.7'}, {'value': '55.8', 'groupId': 'OG002', 'lowerLimit': '50.7', 'upperLimit': '60.8'}]}]}, {'title': 'B/Phuket: Day 0', 'categories': [{'measurements': [{'value': '51.6', 'groupId': 'OG000', 'lowerLimit': '46.4', 'upperLimit': '56.6'}, {'value': '58.8', 'groupId': 'OG001', 'lowerLimit': '53.6', 'upperLimit': '63.7'}, {'value': '57.9', 'groupId': 'OG002', 'lowerLimit': '52.8', 'upperLimit': '62.9'}]}]}, {'title': 'B/Phuket: Day 21', 'categories': [{'measurements': [{'value': '90.7', 'groupId': 'OG000', 'lowerLimit': '87.3', 'upperLimit': '93.4'}, {'value': '92.4', 'groupId': 'OG001', 'lowerLimit': '89.3', 'upperLimit': '94.9'}, {'value': '93.8', 'groupId': 'OG002', 'lowerLimit': '90.9', 'upperLimit': '96.0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Day 0 (pre-vaccination), Day 21', 'description': 'The SP rate is the percentage of participants attaining a reciprocal HI titer of ≥ 40 on Day 21 (the percentage of vaccine recipients with a serum HI titer of at least 1:40 following vaccination). SP rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'PP Set.'}, {'type': 'SECONDARY', 'title': 'Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '386', 'groupId': 'OG000'}, {'value': '383', 'groupId': 'OG001'}, {'value': '387', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'title': 'A/H1N1 (California)', 'categories': [{'measurements': [{'value': '8.55', 'groupId': 'OG000', 'lowerLimit': '7.66', 'upperLimit': '9.53'}, {'value': '8.43', 'groupId': 'OG001', 'lowerLimit': '7.56', 'upperLimit': '9.41'}, {'value': '8.93', 'groupId': 'OG002', 'lowerLimit': '8.01', 'upperLimit': '9.95'}]}]}, {'title': 'A/H3N2 (Hong Kong)', 'categories': [{'measurements': [{'value': '8.41', 'groupId': 'OG000', 'lowerLimit': '7.36', 'upperLimit': '9.61'}, {'value': '8.99', 'groupId': 'OG001', 'lowerLimit': '7.86', 'upperLimit': '10.28'}, {'value': '7.69', 'groupId': 'OG002', 'lowerLimit': '6.73', 'upperLimit': '8.78'}]}]}, {'title': 'B/Brisbane', 'categories': [{'measurements': [{'value': '4.08', 'groupId': 'OG000', 'lowerLimit': '3.69', 'upperLimit': '4.50'}, {'value': '4.09', 'groupId': 'OG001', 'lowerLimit': '3.70', 'upperLimit': '4.52'}, {'value': '3.73', 'groupId': 'OG002', 'lowerLimit': '3.38', 'upperLimit': '4.12'}]}]}, {'title': 'B/Phuket', 'categories': [{'measurements': [{'value': '5.76', 'groupId': 'OG000', 'lowerLimit': '5.16', 'upperLimit': '6.44'}, {'value': '6.17', 'groupId': 'OG001', 'lowerLimit': '5.53', 'upperLimit': '6.90'}, {'value': '6.30', 'groupId': 'OG002', 'lowerLimit': '5.64', 'upperLimit': '7.04'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 0 (pre-vaccination), Day 21', 'description': 'GMFR, the geometric mean of the ratio of GMTs (Day 21/Day 0), was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).', 'unitOfMeasure': 'ratio', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'PP Set.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With at Least One Immediate Complaint', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '96', 'groupId': 'OG000'}, {'value': '108', 'groupId': 'OG001'}, {'value': '106', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '15 minutes post-vaccination', 'description': 'Immediate complaints were defined as any solicited local or systemic reactions. Solicited local reactions included: erythema, swelling, and pain at the injection site and solicited systemic reactions included: fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With at Least One Solicited Local and/or Systemic Reactions', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '314', 'groupId': 'OG000'}, {'value': '321', 'groupId': 'OG001'}, {'value': '321', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 7', 'description': 'Participants were monitored for both solicited local reactions (erythema, swelling, and pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck). Any solicited local or systemic immediate complaint was also included.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With ≥ Severe Solicited Local and Systemic Reaction', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 7', 'description': 'Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Any solicited local or systemic immediate complaint was also included. Intensity of solicited reactions graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening;(4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥severe events included severe and potentially life-threatening events.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 7', 'description': 'Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Intensity of solicited reactions was graded according to the FDA toxicity grade: mild (1); moderate (2); severe (3); (4)-likely to be life-threatening if not treated in a timely manner. Causal relationship with study vaccine was assessed as "definitely not related" (clearly not related),"probably not related" (no medical evidence),"possibly related"(reasonable possibility of cause and effect),"probably related"(plausible biologic mechanism and temporal relationship) or "definitely related"(direct cause and effect relationship). The ≥severe events included severe and "potentially life-threatening" and the related category included "possibly related", "probably related", and "definitely related."', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '94', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '95', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'Participants were monitored for unsolicited TEAEs. An adverse event (AE) or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. An AE was considered treatment-emergent if it was aggravated in severity or frequency following the administration of the study vaccine, up to and including the last visit of the study.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With ≥ Severe Unsolicited TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'The intensity of the unsolicited TEAEs was graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening; (4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥ Severe events included severe and potentially life-threatening events. AE and TEAEs are defined in outcome measure#9.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With ≥ Severe Related Unsolicited TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'The intensity of the unsolicited TEAEs was graded as: mild (1), moderate (2), severe (3) or potentially life threatening (4). The causal relationship with the study vaccine was assessed as "definitely not related" (clearly not related),"probably not related" (no medical evidence), "possibly related" (reasonable possibility of cause and effect), "probably related" (plausible biologic mechanism and temporal relationship) or "definitely related" (direct cause and effect relationship). The ≥severe events included "severe" and "potentially life-threatening" and the related category included "possibly related", "probably related", and "definitely related." AE and TEAEs are defined in outcome measure #9.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With an Occurrence of Death', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'The number of participants with an occurrence of death was assessed.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With at Least One Serious TEAE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'A serious adverse event (SAE) was considered to be any untoward medical occurrence (whether or not considered to be related to the study vaccine) that, at any dose results in death; is life-threatening (at the time of the event); requires inpatient hospitalization (≥ 24 hours) or prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that have not worsened are excluded); results in persistent or significant disability/incapacity; is a congenital abnormality/birth defect; or is another medically important event (e.g. any cases of newly diagnosed cancer). AE and TEAEs is defined in outcome measure #9.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With at Least One AE Leading to Withdrawal', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'An AE or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. The number of participants with at least one adverse event leading to withdrawal was assessed.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'OG000'}, {'value': '398', 'groupId': 'OG001'}, {'value': '401', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'OG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'All NOCDs that may plausibly have an allergic, autoimmune or inflammatory component were reported. Plausibility should be interpreted broadly; however, the only clear exceptions are degenerative conditions such as osteoarthritis, age-related physiologic changes and life-style diseases. In this context, most cancers, cardiac conditions and kidney diseases should be reported. NOCDs were collected from vaccination on Day 0 to the end of the Day 21 visit.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'SAS.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one intramuscular (IM) injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'FG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'FG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '401'}, {'groupId': 'FG001', 'numSubjects': '399'}, {'groupId': 'FG002', 'numSubjects': '402'}]}, {'type': 'Vaccinated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '401'}, {'groupId': 'FG001', 'numSubjects': '398'}, {'groupId': 'FG002', 'numSubjects': '401'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '398'}, {'groupId': 'FG001', 'numSubjects': '397'}, {'groupId': 'FG002', 'numSubjects': '399'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Other than specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'Participants were randomized in a 1:1:1 ratio to receive one of the three lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine at a dose of 30 μg/strain.', 'preAssignmentDetails': 'Participants were healthy adults 18 to 49 years of age assessed during the 2016-2017 influenza season.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '401', 'groupId': 'BG000'}, {'value': '398', 'groupId': 'BG001'}, {'value': '401', 'groupId': 'BG002'}, {'value': '1200', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'BG001', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'BG002', 'title': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '30.5', 'spread': '9.31', 'groupId': 'BG000'}, {'value': '29.9', 'spread': '8.90', 'groupId': 'BG001'}, {'value': '29.4', 'spread': '8.80', 'groupId': 'BG002'}, {'value': '29.9', 'spread': '9.01', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '216', 'groupId': 'BG000'}, {'value': '224', 'groupId': 'BG001'}, {'value': '217', 'groupId': 'BG002'}, {'value': '657', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '185', 'groupId': 'BG000'}, {'value': '174', 'groupId': 'BG001'}, {'value': '184', 'groupId': 'BG002'}, {'value': '543', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '20', 'groupId': 'BG001'}, {'value': '27', 'groupId': 'BG002'}, {'value': '68', 'groupId': 'BG003'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '380', 'groupId': 'BG000'}, {'value': '377', 'groupId': 'BG001'}, {'value': '374', 'groupId': 'BG002'}, {'value': '1131', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '63', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '58', 'groupId': 'BG002'}, {'value': '187', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '17', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '28', 'groupId': 'BG002'}, {'value': '69', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '318', 'groupId': 'BG000'}, {'value': '305', 'groupId': 'BG001'}, {'value': '310', 'groupId': 'BG002'}, {'value': '933', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The Safety Analysis Set (SAS) was defined as all participants who received Quadrivalent VLP Influenza Vaccine.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-08-08', 'size': 1869298, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-05-25T14:41', 'hasProtocol': True}, {'date': '2018-01-24', 'size': 681949, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-05-25T14:42', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'Observer-blind'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1202}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-09-29', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-07', 'completionDateStruct': {'date': '2017-12-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-07-14', 'studyFirstSubmitDate': '2017-10-16', 'resultsFirstSubmitDate': '2023-05-29', 'studyFirstSubmitQcDate': '2017-10-23', 'lastUpdatePostDateStruct': {'date': '2023-08-04', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-07-14', 'studyFirstPostDateStruct': {'date': '2017-10-26', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-08-04', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-12-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain', 'timeFrame': 'Day 21 (post-vaccination)', 'description': 'The GMTs were measured using a HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). Lot-to-lot consistency was based on adjusted GMT ratio for pairwise comparisons of the lots (Lot 1 / Lot 2, Lot 1 / Lot 3, and Lot 2 / Lot 3).'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain', 'timeFrame': 'Day 0 (pre-vaccination) to Day 21', 'description': 'The SC rate is the percentage of participants with either a ≥ 4-fold increase in reciprocal HI titers between Day 0 and Day 21 or a rise of undetectable HI titer (i.e. \\<10) pre-vaccination (Day 0) to an HI titer of ≥40 on Day 21 post-vaccination. SC rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).'}, {'measure': 'Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain', 'timeFrame': 'Day 0 (pre-vaccination), Day 21', 'description': 'The SP rate is the percentage of participants attaining a reciprocal HI titer of ≥ 40 on Day 21 (the percentage of vaccine recipients with a serum HI titer of at least 1:40 following vaccination). SP rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).'}, {'measure': 'Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain', 'timeFrame': 'Day 0 (pre-vaccination), Day 21', 'description': 'GMFR, the geometric mean of the ratio of GMTs (Day 21/Day 0), was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).'}, {'measure': 'Number of Participants With at Least One Immediate Complaint', 'timeFrame': '15 minutes post-vaccination', 'description': 'Immediate complaints were defined as any solicited local or systemic reactions. Solicited local reactions included: erythema, swelling, and pain at the injection site and solicited systemic reactions included: fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck.'}, {'measure': 'Number of Participants With at Least One Solicited Local and/or Systemic Reactions', 'timeFrame': 'Day 0 (post-vaccination) up to Day 7', 'description': 'Participants were monitored for both solicited local reactions (erythema, swelling, and pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck). Any solicited local or systemic immediate complaint was also included.'}, {'measure': 'Number of Participants With ≥ Severe Solicited Local and Systemic Reaction', 'timeFrame': 'Day 0 (post-vaccination) up to Day 7', 'description': 'Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Any solicited local or systemic immediate complaint was also included. Intensity of solicited reactions graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening;(4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥severe events included severe and potentially life-threatening events.'}, {'measure': 'Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions', 'timeFrame': 'Day 0 (post-vaccination) up to Day 7', 'description': 'Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Intensity of solicited reactions was graded according to the FDA toxicity grade: mild (1); moderate (2); severe (3); (4)-likely to be life-threatening if not treated in a timely manner. Causal relationship with study vaccine was assessed as "definitely not related" (clearly not related),"probably not related" (no medical evidence),"possibly related"(reasonable possibility of cause and effect),"probably related"(plausible biologic mechanism and temporal relationship) or "definitely related"(direct cause and effect relationship). The ≥severe events included severe and "potentially life-threatening" and the related category included "possibly related", "probably related", and "definitely related."'}, {'measure': 'Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'Participants were monitored for unsolicited TEAEs. An adverse event (AE) or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. An AE was considered treatment-emergent if it was aggravated in severity or frequency following the administration of the study vaccine, up to and including the last visit of the study.'}, {'measure': 'Number of Participants With ≥ Severe Unsolicited TEAEs', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'The intensity of the unsolicited TEAEs was graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening; (4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥ Severe events included severe and potentially life-threatening events. AE and TEAEs are defined in outcome measure#9.'}, {'measure': 'Number of Participants With ≥ Severe Related Unsolicited TEAEs', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'The intensity of the unsolicited TEAEs was graded as: mild (1), moderate (2), severe (3) or potentially life threatening (4). The causal relationship with the study vaccine was assessed as "definitely not related" (clearly not related),"probably not related" (no medical evidence), "possibly related" (reasonable possibility of cause and effect), "probably related" (plausible biologic mechanism and temporal relationship) or "definitely related" (direct cause and effect relationship). The ≥severe events included "severe" and "potentially life-threatening" and the related category included "possibly related", "probably related", and "definitely related." AE and TEAEs are defined in outcome measure #9.'}, {'measure': 'Number of Participants With an Occurrence of Death', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'The number of participants with an occurrence of death was assessed.'}, {'measure': 'Number of Participants With at Least One Serious TEAE', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'A serious adverse event (SAE) was considered to be any untoward medical occurrence (whether or not considered to be related to the study vaccine) that, at any dose results in death; is life-threatening (at the time of the event); requires inpatient hospitalization (≥ 24 hours) or prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that have not worsened are excluded); results in persistent or significant disability/incapacity; is a congenital abnormality/birth defect; or is another medically important event (e.g. any cases of newly diagnosed cancer). AE and TEAEs is defined in outcome measure #9.'}, {'measure': 'Number of Participants With at Least One AE Leading to Withdrawal', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'An AE or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. The number of participants with at least one adverse event leading to withdrawal was assessed.'}, {'measure': 'Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)', 'timeFrame': 'Day 0 (post-vaccination) up to Day 21', 'description': 'All NOCDs that may plausibly have an allergic, autoimmune or inflammatory component were reported. Plausibility should be interpreted broadly; however, the only clear exceptions are degenerative conditions such as osteoarthritis, age-related physiologic changes and life-style diseases. In this context, most cancers, cardiac conditions and kidney diseases should be reported. NOCDs were collected from vaccination on Day 0 to the end of the Day 21 visit.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Influenza', 'Human', 'RNA Virus Infections', 'Lot Consistency', 'Immunologic', 'Orthomyxoviridae Infections', 'Infection', 'Virus Diseases', 'Vaccine', 'Safety', 'Plant-made', 'Virus-like particle', 'Hemagglutinin'], 'conditions': ['Virus Diseases', 'RNA Virus Infections', 'Respiratory Tract Infections', 'Respiratory Tract Disease', 'Influenza']}, 'referencesModule': {'references': [{'pmid': '33581920', 'type': 'RESULT', 'citation': 'Ward BJ, Seguin A, Couillard J, Trepanier S, Landry N. Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. Vaccine. 2021 Mar 5;39(10):1528-1533. doi: 10.1016/j.vaccine.2021.01.004. Epub 2021 Feb 10.'}]}, 'descriptionModule': {'briefSummary': 'This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine, during the 2016-2017 influenza season, in healthy adults 18-49 years of age. A single dose of one of three consecutive lots of Quadrivalent VLP Influenza Vaccine (30 µg/strain) will be administered to 1,200 participants.', 'detailedDescription': 'This randomized, observer-blind, multicenter, Phase 3 lot consistency study will be conducted at multiple sites in Canada. The composition of the Quadrivalent VLP Influenza Vaccine used in this study includes two influenza A virus strains and two influenza B virus strains based on the 2016-2017 recommended strains for vaccination in the Northern hemisphere.\n\n1,200 healthy male and female participants aged 18 to 49 years will be randomized in a 1:1:1 ratio to one of three lots of the Quadrivalent VLP Influenza Vaccine (30 μg/strain). Participant will participate in this study for approximately 21 days, during which a first visit will be scheduled on Day 0 for screening, eligibility assessment, and vaccine administration; and on Day 21 for blood sample collection for immunogenicity assessment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '49 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be eligible for participation in this study; no protocol waivers are allowed:\n\n1. Participants must be considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study;\n2. Participants have a body mass index (BMI) ≤ 40.0 kg/m\\^2 on Day 0 (pre-vaccination);\n3. Participants must be in good general health prior to study participation with no clinically relevant abnormalities that could jeopardize participant safety or interfere with study assessments as assessed by the Principal Investigator or sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, and vital signs; Note: Participants with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator\'s judgment, the condition is unlikely to confound the results of the study or pose additional risk to the participant by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease six months prior to vaccination. Based on the Investigator\'s judgment, a participant with a more recent stabilization of a disease could also be eligible.\n4. Female participants must have a negative urine pregnancy test result at the Screening/Vaccination visit (Visit 1);\n5. Female participants of childbearing potential must use an effective method of contraception for one month prior to vaccination and agree to continue employing adequate birth control measures for the duration of the study. Abstinent participants should be asked what method(s) they would use, should their circumstances change, and participants without a well-defined plan should be excluded. The following relationship or methods of contraception are considered to be effective:\n\n * Hormonal contraceptives (e.g. oral, injectable, topical \\[patch\\], or estrogenic vaginal ring);\n * Intra-uterine device with or without hormonal release;\n * Male partner using a condom plus spermicide or a sterilized partner (at least one year prior to vaccination);\n * Credible self-reported history of heterosexual vaginal intercourse abstinence until at least the Day 21 visit;\n * Female partner.\n6. Non-childbearing females are defined as:\n\n * Surgically-sterile (defined as bilateral tubal ligation, hysterectomy, or bilateral oophorectomy performed more than one month prior to vaccination); or\n * Post-menopausal (absence of menses for 24 consecutive months and age consistent with natural cessation of ovulation).\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from participating in this study; no protocol waivers are allowed:\n\n1. According to the Investigator\'s opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. \'Uncontrolled\' is defined as:\n\n * Requiring a new medical or surgical treatment during the six months prior to study vaccine administration unless the criteria outlined in inclusion criterion no. 3 can be met (i.e. the Investigator can justify inclusion based upon the innocuous nature of medical/surgical events and/or treatments);\n * Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity, unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5 and is appropriately justified by the Investigator.\n2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or drug abuse which, in the Investigator\'s opinion, would render the participant unable to provide informed consent or unable to provide valid safety observations and reporting;\n3. Any autoimmune disease other than hypothyroidism with stable replacement therapy; or any confirmed or suspected immunosuppressive condition or immunodeficiency including known or suspected human immunodeficiency virus (HIV), hepatitis B or C infection, or the presence of lymphoproliferative disease;\n4. Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization and up to blood sampling on Day 21. Immunization on an emergency basis will be evaluated case-by-case by the Investigator;\n5. Administration of any adjuvanted or investigational influenza vaccine within 24 months prior to randomization or planned administration prior to the completion of Day 21;\n6. Administration of any "standard", non-adjuvanted influenza vaccine (e.g. live attenuated trivalent/quadrivalent inactivated influenza vaccine intranasal or split trivalent/quadrivalent inactivated influenza vaccine by either intradermal or IM route) within 24 months prior to randomization and up to completion of the Day 21 visit;\n7. Use of any investigational or non-registered product within 30 days prior to randomization or planned use during the study period. Participants may not participate in any other investigational or marketed drug study while participating in this study until the Day 21 visit. Participation in observational studies is permitted;\n8. Treatment with systemic glucocorticoids at a dose exceeding 10 milligrams (mg) of prednisone (or the equivalent) per day for more than seven consecutive days or for ten or more days in total, within one month of study vaccine administration; or any other cytotoxic or immunosuppressant drug, or any immunoglobulin preparation within three months of vaccination and until the completion of the Day 21 visit. Low doses of nasal or inhaled glucocorticoids and topical steroids are permitted;\n9. Any significant disorder of coagulation including, but not limited to, treatment with warfarin derivatives or heparin. Persons receiving prophylactic anti-platelet medications (e.g. low-dose aspirin \\[no more than 325 mg/day\\]) and without a clinically apparent bleeding tendency are eligible. Participants treated with new generation drugs that do not increase the risk of IM bleeding (e.g. clopidogrel) are also eligible.\n10. History of allergy to any of the constituents of the Quadrivalent VLP Influenza Vaccine or a tobacco allergy;\n11. History of anaphylactic allergic reactions to plants or plants components;\n12. Any history of serious asthma (e.g. status asthmaticus, hospitalization for asthma control) in the last three years;\n13. Use of antihistamines 48 hours prior to study vaccination;\n14. The use of prophylactic medications (e.g. acetaminophen/paracetamol, aspirin, naproxen, or ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to vaccination. Participant discovered to have taken a prophylactic medication to prevent or pre empt symptoms due to vaccination within the 24 hours prior to planned randomization must be delayed until at least the 24-hour period is met;\n15. Participants who have a dermatological condition at the injection site that may interfere with injection site reaction rating;\n16. Participant who have received a blood transfusion within 90 days prior to study vaccination;\n17. Any female participant who has a positive or doubtful pregnancy test result prior to vaccination or who is lactating;\n18. Presence of any febrile illness (including oral temperature (OT) ≥ 38.0 ˚C within 24 hours prior to vaccination). Such participants may be re-evaluated for enrolment after resolution of illness;\n19. Cancer or treatment for cancer within three years of study vaccine administration. Participants with a history of cancer who are disease-free without treatment for three years or more are eligible. Individuals with treated and uncomplicated basal cell carcinoma of the skin or with non-treated, non-disseminated local prostate cancer are eligible;\n20. Participants identified as an Investigator or employee of the Investigator or clinical site with direct involvement in the proposed study, or identified as an immediate family member (i.e. parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study or any employee of Medicago. Immediate family members of the Investigator or employees of a clinical site can participate in the study at another clinical site, as long as the Investigator or employees are not involved in the study at that site;\n21. Participant with a history of Guillain-Barré syndrome.'}, 'identificationModule': {'nctId': 'NCT03321968', 'briefTitle': 'Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults', 'organization': {'class': 'INDUSTRY', 'fullName': 'Medicago'}, 'officialTitle': 'A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of Age', 'orgStudyIdInfo': {'id': 'CP-PRO-QVLP-011'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Quadrivalent VLP Influenza Vaccine - Lot 1', 'description': 'Participants received one intramuscular (IM) injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.', 'interventionNames': ['Biological: Quadrivalent VLP Influenza Vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.', 'interventionNames': ['Biological: Quadrivalent VLP Influenza Vaccine']}, {'type': 'EXPERIMENTAL', 'label': 'Quadrivalent VLP Influenza Vaccine - Lot 3', 'description': 'Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.', 'interventionNames': ['Biological: Quadrivalent VLP Influenza Vaccine']}], 'interventions': [{'name': 'Quadrivalent VLP Influenza Vaccine', 'type': 'BIOLOGICAL', 'description': 'Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine', 'armGroupLabels': ['Quadrivalent VLP Influenza Vaccine - Lot 1', 'Quadrivalent VLP Influenza Vaccine - Lot 2', 'Quadrivalent VLP Influenza Vaccine - Lot 3']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Halifax', 'state': 'Nova Scotia', 'country': 'Canada', 'facility': 'Site 205', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'city': 'Burlington', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Site 208', 'geoPoint': {'lat': 43.38621, 'lon': -79.83713}}, {'city': 'Guelph', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Site 207', 'geoPoint': {'lat': 43.54594, 'lon': -80.25599}}, {'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Site 202', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Chicoutimi', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Site 204', 'geoPoint': {'lat': 48.41963, 'lon': -71.06369}}, {'city': 'Gatineau', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Site 203', 'geoPoint': {'lat': 45.47723, 'lon': -75.70164}}, {'city': 'Lévis', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Site 201', 'geoPoint': {'lat': 46.80326, 'lon': -71.17793}}, {'city': 'Pointe-Claire', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Site 209', 'geoPoint': {'lat': 45.44868, 'lon': -73.81669}}, {'city': 'Toronto', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Site 206'}, {'city': 'Victoriaville', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Site 210', 'geoPoint': {'lat': 46.05007, 'lon': -71.96579}}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Medicago'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Medicago', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}